Medical information related to P. aeruginosa infections (n = 210)
| Parameter | Frequency (%) |
|---|---|
| Source of infection acquisition# | |
| Community-acquired | 178 (84.8) |
| Hospital-acquired | 32 (15.2) |
| Primary site of infection | |
| Respiratory tract | 81 (38.6) |
| Skin and soft tissue | 48 (22.9) |
| Urinary tract | 40 (19.0) |
| Surgical site | 15 (7.1) |
| Bloodstream | 7 (3.3) |
| Bone | 5 (2.4) |
| Others | 14 (6.7) |
| Season of infection acquisition | |
| Winter | 61 (29.0) |
| Spring | 45 (21.4) |
| Summer | 43 (20.5) |
| Fall | 61 (29.0) |
| Hospitalization within the last three months | |
| No | 127 (60.5) |
| Yes | 83 (39.5) |
| Use of antibiotics within the last three months | |
| No | 127 (60.5) |
| Yes | 83 (39.5) |
| Use of corticosteroids within the last three months | |
| No | 177 (84.3) |
| Yes | 33 (15.7) |
| Previous immunosuppressant/chemotherapy use within the last three months | |
| No | 198 (94.3) |
| Yes | 12 (5.7) |
| Invasive procedures prior to infection acquisition | |
| No | 167 (79.5) |
| Major surgery | 13 (6.2) |
| Double J stent | 11 (5.2) |
| Othersa | 19 (9.0) |
| Infection localization | |
| Localized | 193 (91.9) |
| Sepsis | 12 (5.7) |
| Bacteremia | 5 (2.4) |
| Resistance pattern of P. aeruginosa | |
| Non-MDR bacteria | 111 (52.9) |
| MDR bacteria | 99 (47.1) |
| 30-days, all-cause mortality^ | |
| Survived | 196 (95.1) |
| Died | 10 (4.9) |
a Foley, central venous line, endoscopy, venous access port, dialysis/acute renal replacement therapy, cystoscopy, ureteroscopy. # Community-acquired infections are those acquired within 48 hours of hospital admission, while hospital-acquired infections are those that become evident after 48 hours of hospitalization. ^ The percentages were calculated based on 206 individuals after excluding patients who were discharged against medical advice. MDR: multidrug-resistant